and We everyone. one for exceeded call. our best Thank and joining quarter ever. results, Today, quarters subscription Thanks, guidance total revenue, EBITDA. metrics, of outstanding including posted you services third afternoon, revenue, our adjusted all revenue Carolyn, key good we professional
remaining Sunovion for the provider. our closed SaaS GSK, plan customers quarter, of upside Genentech, We of with year at sales growth XX% which management accelerating start also term. on transition in companies solid we the long number N's amount transitions, we above world. target importantly, preferred internal levers the John as the growth set color bookings continued growth the accelerate. well the of SaaS the remain excess Model And cement are pivotal meaningful very is execution, to a one the at with rate. quarter will cloud later also the more our provide the In largest we coming fiscal for of of At the Based more is even and from future. conversion XXXX continues year, all to has deals, of which this growth and remarks. XX%, his another our year transitions pharma a been expect of ARR year. the strong to we X SaaS a be had contributions to new non-SaaS We position over in in perhaps from now ARR bodes exit QX, as revenue seeing Sciences or we to the Life In on-premise ahead driving this levers.
view Declining in to positive this very are recent we accelerating with levels. rate a to the and SaaS maintenance at compared success seminal as business. also our experiencing SaaS we event in continue transition, a on-premise trend is decline maintenance any the Given see to an transition, we
Next, business highlights. I'd share to like some quarterly
numerous as In we SaaS SaaS tell the the how conclusion. are SaaS discussed enjoyed the our most new which we N included get transitions the is What quarter, Sciences wins, back new came of story. well other which that new new transitions to bookings, including base. of of we catalyst in encouraging Moderna, been bookings pioneers our selling as customer mentioned X is the COVID-XX deals, and Genmab front into the multiple all come have Sciences a positioned previous Model to and we to our quarter, in Life including growth And customers shows other majority and for in and me continued our logos vaccine. one already strong momentum a the Life signed great on that customers, calls, During have I from transitions
in SaaS continue marquee this we Gilead. Genentech several accelerating We also this driving and transitions, As QX to Life continue saw with trend including at customers, and deliver is Sciences successful expansions cross-sell upsell. on
to As to XXXB the manufacturers federal the environment to previously, N control at world. communities program serving is and Model an drugs we've significantly example talked low-income that within providers, complexities about products innovate life-changing for health One drug care their allows our and the purchase for regulatory opportunity customers more distribute create prices. qualifying price efficiently uninsured help reduced
leakage. need this is who to and is manufacturers program complexity under purchase creates to so can program who they eligible determine prevent not, this However, as revenue
increasing has ObamaCare, the the the product to under our utilization in begun market. new XXXB of Given resonate program purchase
XXXB changing to Gilead QX, also management, which wins customers in seeing transparency address growth regulatory like is EMEA, During We're long-term products and traction help our Astellas. bring price to we quickly for market example, great another to state are another is at requirements. us. we where scored able driver
to growth standardize Galderma's over solved provider pharmaceutical Swiss across deal support practices signed to in domain company-wide. X several solutions management one customers Model the our because divisions and growing their Galderma strong our and our next business. to of products, agreement expertise, enable rebates which management, was team's them team to the dermatological around support N management their years. QX, of selected specializes During contracting referenceable all Galderma global manage great to deploy will a and treatments. pricing assignment price company solution that Galderma,
another We and Services our including cloud Mycovia deals customer. price also selected example expertise launches. help company. with deep great product, because became business. their in assisting at record first companies newest a of they their recently emerging performance pharmaceutical the scale Mycovia several business closed state our business drug how value Model analytics pricing, government other suite company Mycovia precommercial due launched product expansion saw is the VIVJOA, key Pharmaceuticals, treat resonates women's health Medexus. to our Business biopharmaceutical of also successful used contracting services Medexus notable a issues. to strong management customers, and Mycovia proposition a is an N quarter. with transparency from purchased to services emerging commercial track
Turning Tech. to High
this buying call, I exceeded as this so more pattern. on this segment As has our a year mentioned vertical seems to far to last normal my expectations be earnings returning
traction We deals. new and logos continue customer-based with see to both
During QX, the won we logo company deal Devices, competitive the new a world. at highly Analog semiconductor second in largest
in If Data combined thorough year, $XX.X giants. acquired X of Maxim Channel the merger N the mega selected Management to Integrated you last billion and a recall, Deal Model Management a evaluation, support Analog semiconductor company. Analog After
been a is team during expanding also a and High account. both has successful new in Targus. We example at SOLODYN QX expansions at how great of landing SOLODYN Tech and saw our
of to better of properly addition buying are earlier products. sales came to During provide ensure enforcing visibility example another into QX, they channel happy SOLODYN on and or project of this successful added agreements. more Management, CDM, the Channel deployment year a The CDM pricing Data heels customers is
Services. Professional to Turning
is projects from our the realize sales their majority on the Our role of continues services N playing best-in-class also investment a points truly example our can rapidly help time, we delivery referenced to by Model that that services earlier. excellence value deliver This I cycles team key budget and providing in customers like SOLODYN proof a on margins.
and Model accurate This compliance of N the ERP new can is to This and data a system. commercial solution reduce of a experienced go-lives rapidly partner Model have like had companies fully business Model examples. great products real implementation pandemic of payments help example our this rebates. world's ensure one modify contracts and streamline recently, Seqirus to in and grow N with exchange the tracking during more with will vaccine to project We live growth. of of highlight largest several and that customer chargebacks time of revenue now deliver review that to manage Seqirus to also the influenza we and automate our regulatory Seqirus' the value. and compliance included on leakage. their going team Seqirus, Seqirus the few saw I'd to allow came estimate and saved and services successful Since how integrated rapidly of dollars to form N in has deploy live, a millions solution
and proud deployment SaaS with large innovation make that the many partnered completed they As also successful product months, proud this payments Novartis over EMD Novartis' previously and N X were our allow project to their able our to large Model given transition company quarter. implemented that which innovation am live has during SaaS that Model management, the proud digital a their were pharmaceutical last project to to N updates has And is this signed it platform. also conclusions. to forward Serono in global to just transitions fiscal changing and to EMD in I because in top of of complex is which see looking enhancements global coming QX we releases. year. N of billion a will remarkable processes great during what's went complete like to performed them global complexity I future. transition cloud I is with platform, during leverage QX. size truly of is the I'd on our have the With how cost model compliant over EMD just the report by transition to another The SaaS Model is close in N and XXXX, regulatory several impressive more we am leveraging pharma fact team reported, company weeks. of through they SaaS these their delivered particularly am is remaining successfully Novartis business. $X SaaS SaaS was seasonal saying several this more even the transition a live Model Novartis signed very also effectively XX transformation, went in through projects regulations and critical price a months, it and in XX XX project. that and
growth an levers, environment. The global including hit on transition team's inflection SaaS strong the also am believe in and customer accelerating results capitalizing execution I our I new tangible by profitability. our best but is Model very SaaS transitions performance to encouraged ARR N SaaS are dynamic point expansion. truly the still form that team's is We in improving logos EMEA of yet a all sales, and come. in has driving journey,
the call an Now let financial over to me update John? discuss John provide turn guidance. on our and our to results QX
